Abstract
An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.The particular advantage of this drug is the low incidence of troublesome side effects.
MeSH terms
-
Adult
-
Aged
-
Alkenes / therapeutic use
-
Anabolic Agents / adverse effects
-
Anabolic Agents / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Chronic Disease
-
Diethylstilbestrol / adverse effects
-
Diethylstilbestrol / therapeutic use
-
Estrogen Antagonists*
-
Ethylamines / adverse effects
-
Ethylamines / therapeutic use*
-
Female
-
Humans
-
Middle Aged
-
Recurrence
Substances
-
Alkenes
-
Anabolic Agents
-
Estrogen Antagonists
-
Ethylamines
-
Diethylstilbestrol